Laboratory of Cellular Oncology, National Cancer Institutegrid.48336.3a, National Institutes of Health, Bethesda, Maryland, USA.
Aura Biosciences, Cambridge, Massachusetts, USA.
J Virol. 2022 Apr 13;96(7):e0185721. doi: 10.1128/jvi.01857-21. Epub 2022 Mar 14.
Human papillomaviruses (HPVs) are nonenveloped double-stranded DNA viruses that utilize heparan sulfate proteoglycans (HSPGs) as initial attachment factors prior to cell entry and infection. While extensively characterized, the selective interaction between HPV and HSPGs is generally studied using standard conditions, which fail to account for the effects that media additives, such as fetal bovine serum (FBS), can have on viral binding. As environmental conditions and growth factors associated with wound healing are thought to play a role in natural HPV infection, we sought to investigate the effects that serum or platelet extracts could have on the binding and infectivity of HPV. Here, we demonstrate that high concentrations of FBS and human serum greatly inhibit HPV16 binding, and that for FBS, this effect results from the obstruction of cell surface HSPGs by serum-derived heparin-binding proteins (HBPs). Surprisingly, we found that under these conditions, HPV particles utilize 6O-sulfated chondroitin sulfate proteoglycans (CSPGs) as initial binding receptors prior to infection. These findings were corroborated by small interfering RNA (siRNA)-mediated knockdown experiments, as well as through a cancer cell line screen, where we identified a strong association between viral binding in high serum and the expression of chondroitin sulfate biosynthesis genes. Furthermore, HPV binding in the presence of human platelet lysate also demonstrated an increased dependance on CSPGs, suggesting a possible role for these receptor proteoglycans in active wound healing environments. Overall, this work highlights the significant influence that serum/platelet factors can have on virus binding and identifies CSPGs as alternative cell attachment receptors for HPV. Heparan sulfate proteoglycans (HSPGs) have previously been identified as primary attachment factors for the initial binding of human papillomaviruses (HPVs) prior to infection. Here, we demonstrate that , HPV binding to HSPGs is strongly dependent on the surrounding experimental conditions, including the concentration of fetal bovine serum (FBS). We found that high concentrations of FBS can block HSPG-binding sites and cause a dependence on 6O-sulfated chondroitin sulfate proteoglycans (CSPGs) as alternative initial viral receptors. Further, we demonstrate that use of a human-derived alternative to FBS, human platelet lysate, also occludes HSPG-dependent binding, causing a shift toward CSPGs for viral attachment. As HPV infection of basal epithelial cells is thought to occur at sites of microtrauma with exposure to high serum levels and platelet factors, these unexpected findings highlight a possible role for CSPGs as important cellular receptors for the binding and infectivity of HPV .
人乳头瘤病毒(HPV)是无包膜的双链 DNA 病毒,在进入细胞和感染之前,利用硫酸乙酰肝素蛋白聚糖(HSPG)作为初始附着因子。尽管已经广泛研究了 HPV 与 HSPG 之间的选择性相互作用,但通常是在标准条件下进行研究的,这些条件不能解释培养基添加剂(如胎牛血清(FBS))对病毒结合的影响。由于与伤口愈合相关的环境条件和生长因子被认为在自然 HPV 感染中发挥作用,因此我们试图研究血清或血小板提取物对 HPV 结合和感染性的影响。在这里,我们证明了高浓度的 FBS 和人血清极大地抑制了 HPV16 的结合,并且对于 FBS,这种作用是由于血清衍生的肝素结合蛋白(HBPs)阻塞了细胞表面 HSPG。令人惊讶的是,我们发现,在这些条件下,HPV 颗粒在感染之前利用 6O-硫酸软骨素蛋白聚糖(CSPG)作为初始结合受体。这些发现得到了小干扰 RNA(siRNA)介导的敲低实验以及癌细胞系筛选的证实,在筛选中,我们发现病毒在高血清中的结合与硫酸软骨素生物合成基因的表达之间存在很强的相关性。此外,人血小板裂解物存在时 HPV 的结合也表现出对 CSPG 的依赖性增加,表明这些受体蛋白聚糖在活跃的伤口愈合环境中可能具有重要作用。总的来说,这项工作强调了血清/血小板因子对病毒结合的显著影响,并确定 CSPG 是 HPV 的替代细胞附着受体。硫酸乙酰肝素蛋白聚糖(HSPG)先前被鉴定为人类乳头瘤病毒(HPV)感染前初始结合的主要附着因子。在这里,我们证明,HPV 与 HSPG 的结合强烈依赖于周围的实验条件,包括胎牛血清(FBS)的浓度。我们发现,FBS 的高浓度可以阻断 HSPG 结合位点,并导致对 6O-硫酸软骨素蛋白聚糖(CSPG)作为替代初始病毒受体的依赖性。此外,我们证明,使用人来源的 FBS 替代物,人血小板裂解物,也会阻断 HSPG 依赖性结合,导致病毒附着时向 CSPG 转移。由于 HPV 感染基底上皮细胞被认为发生在微创伤部位,暴露于高血清水平和血小板因子,这些意外发现强调了 CSPG 作为 HPV 结合和感染性的重要细胞受体的可能作用。